drugset / Trial / NCT06649695
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
Phase 2
Active not recruiting
30 enrolled
European Myeloma Network B.V.
Janssen Research & Development, LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter open-label, phase 2 study in participant with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the benefit of teclistamab
Timeline
- Start
- 2025-07-02
- Primary completion
- 2028-09
- Completion
- 2028-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Teclistamab | Monoclonal antibody | — | Subcutaneous |